Update on the emerging role of telavancin in hospital-acquired infections

Citations of this article
Mendeley users who have this article in their library.


Telavancin is a lipoglycopeptide that has activity against gram-positive aerobic and anaerobic bacteria. It has activity against methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus and non-Van-A strains of vancomycin-resistant entero-cocci. It has been approved by the US Food and Drug Administration (FDA) for complicated skin and skin structure infections and hospital-acquired pneumonia. There is a need for more clinical studies to determine the role of telavancin in treating bacteremia and prosthetic device infections. In this review, we discuss the published data on the use of telavancin in treating hospital-acquired infections and provide an update on new research.




Nnedu, O. N., & Pankey, G. A. (2015). Update on the emerging role of telavancin in hospital-acquired infections. Therapeutics and Clinical Risk Management, 11, 605–610. https://doi.org/10.2147/TCRM.S57376

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free